Literature DB >> 3011904

High and low affinity receptors for interleukin 2: implications of pronase, phorbol ester, and cell membrane studies upon the basis for differential ligand affinities.

R J Robb, C M Rusk.   

Abstract

Cellular binding sites for IL 2 exist in two forms which differ with respect to their apparent affinity for the factor. The present studies were designed to evaluate various models for the difference. Receptor-mediated internalization and covalent receptor-ligand coupling were discounted as explanations on the basis of ligand binding and elution studies on permeabilized cells and cell membranes. Phosphorylation of the receptor during activation of protein kinase C failed to modulate the ratio of high and low affinity sites, demonstrating that it also did not provide a potential mechanism. Selective destruction of low affinity receptors with pronase, on the other hand, indicated that the two forms of binding sites differed significantly in their cell surface structure. Either the two types of receptor consist of distinct molecules or the conformation of the high affinity binding sites renders them more resistant to proteolysis. Antibody inhibition studies revealed that the high affinity receptors remaining after protease treatment and their low affinity counterparts both utilized the same ligand-binding component. Thus, this result ruled out the possibility of two totally distinct receptor structures. Together, the findings support the hypothesis that other membrane components modify the conformation of the ligand-binding polypeptide to confer a high affinity protease-resistant configuration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011904

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Human IFN-gamma up-regulates IL-2 receptors in mitogen-activated T lymphocytes.

Authors:  M A Rodriguez; J B De Sanctis; A M Blasini; M Leon-Ponte; I Abadi
Journal:  Immunology       Date:  1990-04       Impact factor: 7.397

2.  Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo.

Authors:  Yuri Kasama; Satoshi Sekiguchi; Makoto Saito; Kousuke Tanaka; Masaaki Satoh; Kazuhiko Kuwahara; Nobuo Sakaguchi; Motohiro Takeya; Yoichi Hiasa; Michinori Kohara; Kyoko Tsukiyama-Kohara
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

3.  Effect of the new immunoregulator AS-101 on in vitro functions of mononuclear cells from patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcon-Segovia; B Sredni; M Albeck
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

4.  Recombinant human tumor necrosis factor-alpha. Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils.

Authors:  Y H Atkinson; W A Marasco; A F Lopez; M A Vadas
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

5.  Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5.

Authors:  M S Loughnan; C J Sanderson; G J Nossal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

6.  Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

7.  Evidence for two extracellular domains in the human interleukin-2 receptor: localization of IL-2 binding.

Authors:  D A Shackelford; I S Trowbridge
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

8.  Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.

Authors:  D G Morris; H F Pross
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

Review 9.  On the role of sIL-2R measurements in rheumatoid arthritis and cancers.

Authors:  Anna Maria Witkowska
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.